[Congressional Record Volume 147, Number 152 (Tuesday, November 6, 2001)]
[House]
[Pages H7726-H7727]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]
ANTIBIOTIC RESISTANCE
The SPEAKER pro tempore. Under the Speaker's announced policy of
January 3, 2001, the gentleman from Ohio (Mr. Brown) is recognized
during morning hour debates for 5 minutes.
Mr. BROWN of Ohio. Mr. Speaker, in response to the emergent threats
of bioterrorism, Congress will take concrete steps in the coming weeks
to strengthen our Nation's public health infrastructure. To fully
prepare for the potential bioterrorist attacks, we will have to deal
with a wide variety of public health issues including vaccinations and
food safety and government stockpiling of antibiotics. In doing so, we
must not forget to address the issue of antibiotic resistance.
The links between antibiotic resistance and bioterrorism are clear.
Antibiotic resistant strains of anthrax or other bacterial agents would
be extremely lethal biological weapons, and they are already a reality.
According to the Journal of the American Medical Association, during
the Cold War, Russian scientists engineered an anthrax strain that was
resistant to the tetracycline and penicillin classes of antibiotics. We
can only assume that anthrax and other bacterial agents could also be
engineered to resist antibiotics, including new valuable antibiotic
therapies like Cipro.
Antibiotic resistance is also relevant to the threat of bioterrorism
in other significant ways. The overuse and the misuse of antibiotics by
physicians, patients, and hospitals renders bacterial agents more
resistant to the antibiotic drugs that they are exposed to and could
leave the Nation poorly prepared for a biological attack.
It is a vicious cycle because the threat of bioterrorism can lead to
the overuse and the abuse of antibiotics, people taking Cipro when they
do not need it, for example, which in turn could make these antibiotics
less effective against the agents of bioterrorism.
During the last couple of months, thousands of Americans have been
prescribed the antibiotic Cipro because of a legitimate risk of
exposure to anthrax. That use of antibiotics is appropriate. But the
thousands more who have sought antibiotic prescriptions for Cipro
without any indication of need or even a risk of infection can be a
problem.
The widespread use of Cipro will kill bacteria that are susceptible
to the drug, but will leave behind bacteria that are not. Those
bacteria that are not killed will then have the opportunity to thrive
and develop an even greater resistance to Cipro, requiring an
alternative antibiotic to kill them and diminishing the overall
effectiveness of Cipro.
Many pathogenic bacteria that cause severe human illnesses are
already resistant to older antibiotics like penicillin, as we all know.
That is one reason newer antibiotics like Cipro are used to treat
dangerous infections.
[[Page H7727]]
With diseases like anthrax, it is important to find an effective
therapy quickly. Any delay can result in the death of a patient, or in
the case of a larger exposure, in the deaths of thousands of
individuals. If the U.S. and the rest of the world begin using Cipro
haphazardly, that antibiotic could lose its effectiveness also.
{time} 1245
To adequately prepare for a bioterrorist attack, State and local
health departments must be equipped to rapidly identify and respond to
antibiotic-resistant strains of anthrax and other lethal agents.
And to ensure the continued efficacy of our antibiotic stockpile, we
must isolate emerging antibiotic-resistant pathogens, track antibiotic
overuse and misuse, and monitor the effectiveness of existing
treatments over time.
Surveillance also provides the data needed to prioritize the research
and development of new antibiotic treatments.
Drug-resistant pathogens are already a growing threat to every
American. Examples of important microbes that are rapidly developing
resistance to available antimicrobials include the bacteria that cause
pneumonia, ear infections, meningitis, and skin, bone, lung or
bloodstream infections.
That list also includes food-borne infections like salmonella, and
the Nation's food supply could be a future target of bioterrorism.
Under last year's Public Health Threats and Emergencies Act,
sponsored by the gentleman from North Carolina (Mr. Burr) and the
gentleman from Michigan (Mr. Stupak), Congress authorized a grant
program that would equip State and local health departments to identify
and to track antibiotic resistance.
To build upon this already authorized program, the gentleman from New
York (Mr. Boehlert) and I have asked the Committee on Appropriations to
include at least $50 million for this grant program in the Homeland
Security Supplemental Appropriations bill. I urge Members on both sides
of the aisle to support that request.
Let our appropriators know that this funding is critical to the
viability of our main weapons against bioterrorism and other infectious
diseases now and in the future.
____________________